Akèy › Lukemi lenfositè kwonik › Texas › Dallas
Etid klinik pou Lukemi lenfositè kwonik nan Dallas, TX
10 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan ak bò kote Dallas (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Ap rekriteFaz 3
- Texas Oncology Baylorcharles A Sammons Cancer Center, Dallas
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Ap rekriteFaz 1
- Baylor University Medical Center, Dallas
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Ap rekriteFaz 1/2
- Baylor Scott & White Health, Dallas
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Ap rekriteFaz 1
- UT Southwestern Medical Center, Dallas
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Ap rekriteFaz 2
- Texas Oncology - Sammons Cancer Center, Dallas
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Ap rekriteFaz 1/2
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Ap rekriteFaz 3
- University of Texas - Southwestern Medical Center /ID# 266528, Dallas
Study of SGR-1505 in Mature B-Cell Neoplasms
Ap rekriteFaz 1
- University of Texas Southwestern, Dallas
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Ap rekriteFaz 1
- University of Texas Southwestern Medical Center, Dallas
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Ap rekriteFaz 1/2
- UT Southwestern Medical Center, Dallas
Etid Lukemi lenfositè kwonik nan lòt vil
- Boston, MA31 etid
- Columbus, OH28 etid
- Durham, NC27 etid
- Washington, DC22 etid
- Seattle, WA20 etid
- Rochester, MN19 etid
- New York City, NY18 etid
- Houston, TX17 etid
- Baldwin Park, CA16 etid
- Milwaukee, WI15 etid
- Cincinnati, OH14 etid
- Chicago, IL14 etid
Lòt etid nan Dallas
- Kansè nan tete55 etid
- Kansè Poumon ki pa ti selil52 etid
- Kansè Metastatik42 etid
- Ensifizyans kadyak42 etid
- Kansè (tout kalite)37 etid
- Kansè pwostat36 etid
- Kansè kolorektal33 etid
- Obèsite30 etid
- Kansè ovè28 etid
- Kansè vejik27 etid
- Kansè poumon27 etid
- Kansè Endomèt24 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.